Table of Contents
- What are microbicides?
- How would microbicides work?
- Are microbicides currently available?
- What is happening in microbicide research?
- Would microbicides eliminate the need for condoms?
- Would microbicides protect against all STDs?
- What if a woman wants to get pregnant?
- Would microbicides be safe?
- How would microbicides benefit men?
- How would microbicides benefit women with HIV?
- Why do we need microbicides if we will eventually have an HIV vaccine?
- How much will microbicides cost, and will people be able to afford them?
- What about Nonoxynol-9 (N-9)?
- Taking care of yourself
Microbicides are products being developed to reduce the spread of HIV and other sexually transmitted diseases (STDs). Microbicides could come in many forms, including gels, creams, suppositories, films, lubricants, sponges, or vaginal rings. They could be used in the vagina or rectum.
Microbicides could work in different ways:
- Killing germs such as bacteria and viruses or making them inactive
- Changing the condition of the vagina or rectum to make infection less likely
- Blocking infection by creating a barrier between the germ and the cells of the vagina or rectum
- Preventing the germ from spreading after it has entered the body
No. Scientists are testing many products to see whether they help protect against infection with HIV and/or other STDs. Some of these products have proven safe enough in lab studies that they are now being tested in people. However, no safe and effective microbicide is currently available to the public.
Microbicides have been in development for the past 15 years. A number of studies conducted on the early products failed to find an effective microbicide.
However, there is hope that a new group of microbicides that contain HIV drugs will be more effective. Unlike earlier products, these newer microbicides do not have to be applied at the time of sex. They may be used daily as a gel or possibly as a vaginal ring that may only need to be inserted once a month.
Vaginal and Rectal Gels
Promising results were reported in July 2010 from a large study called CAPRISA 004. This study of 889 HIV-negative women in South Africa showed that when women used a one percent gel version of the HIV drug Viread (tenofovir) inside the vagina, two out of every five HIV infections were prevented. These study results provide early proof that HIV drug-based microbicides, in particular tenofovir gel, can help protect women against HIV.
The CAPRISA 004 study also showed that women who used the tenofovir one percent gel had half as many infections caused by herpes simplex virus (HSV-2), or genital herpes. This is important because people infected with HSV-2 are more likely to get infected with HIV as well as to spread it to others.
Unfortunately, a similar study of tenofovir one percent vaginal gel among over 5000 HIV-negative women in Uganda, South Africa, and Zimbabwe was not successful. This study, called the VOICE study (MTN 003), was stopped in the fall of 2011 because it did not work to prevent HIV infections. However, the tenofovir gel appeared to be safe, without major side effects.
There is another study being done now to measure the effectiveness of one percent tenofovir vaginal gel in up to 2900 HIV-negative women in South Africa. This is called the FACTS 001 study; its results are expected late in 2014 or in early 2015. Researchers hope that the FACTS 001 study will help us understand why the CAPRISA study showed the gel worked and the VOICE study did not.
A related study testing the safety of one percent tenofovir gel in pregnant and breastfeeding women found no concerning side effects for either mothers or babies related to the gel. Although this study was small (90 women), it showed promising results.
Researchers are also testing a version of tenofovir gel designed for rectal use. This study (MTN 017) is exploring the safety and acceptance of the rectal gel in transgender women and men who have sex with men in Peru, South Africa, Thailand, and the US.
There is also hope that vaginal rings containing HIV drugs can prevent the spread of HIV. The ring is flexible and designed to be placed deep inside the vagina against the cervix (entrance to the womb), where it stays for one month. The benefit of using a vaginal ring compared to a vaginal gel is that women would not have to insert the microbicide ring as often as the gel.
Two studies, the ASPIRE study (MTN 020) and the Ring Study (IPM 027), are looking at the effectiveness of a vaginal ring containing an HIV drug called dapivirine (a non-nucleoside reverse transcriptase inhibitor) to prevent the spread of HIV. The ASPIRE study is looking at the ring's effects in over 3000 women from Malawi, South Africa, Uganda, Zambia, and Zimbabwe. The Ring Study is looking at the effect of the ring in 1650 women from Rwanda and South Africa. Results from both studies are expected in 2015.
Researchers are also looking at a vaginal ring containing a combination of two HIV drugs: dapivirine and Selzentry (maraviroc). This ring is not as far along in testing as the dapivirine-only ring. However, an early study showed that the ring appears to be safe and well-tolerated. It also showed that only the dapivirine drug was present in a high enough level to prevent HIV infection in cervical cells.
Scientists in the FAME-02 study found that a vaginal film containing dapivirine delivered enough drug to vaginal tissue to prevent HIV infection when tested in the laboratory.
Multipurpose Prevention Technologies
Multipurpose Prevention Technologies (MPTs) provide ways of preventing more than one thing in one device. For example, MPTs may prevent pregnancy and HIV, or they may prevent HIV and several other STDs. Having methods that combine prevention of pregnancy and STDs (including HIV) would be more convenient and likely lead to more consistent and therefore more effective use.
Researchers are studying several methods for combining prevention technologies, including a vaginal ring containing both a hormonal contraceptive (to prevent pregnancy) and an HIV drug (to prevent HIV; a form of Pre-Exposure Prophylaxis, or PrEP). It can be inserted well before sex, stay there for up to three months, and is not usually felt by either partner. Early studies have shown that the ring appears to be effective in preventing monkeys from getting HIV and from getting pregnant. The next step is for the ring to be tested in women in clinical research trials.
No. When used consistently and correctly, male or female condoms are likely to provide better protection against HIV and other STDs than microbicides, so they are still the best choice. But for people who do not have access to condoms, or who cannot or will not use condoms, microbicides would provide another option. This is especially true for women whose male partners refuse to use condoms. Microbicides could be used without the knowledge of women's sexual partners, thereby putting the power of prevention directly in women's hands. Using microbicides could save lives and have a major impact in reducing the spread of HIV.
Many of the microbicides being tested work against HIV and at least one other STD. In time, a product may be developed that combines different microbicides and could prevent a wide range of STDs, including HIV (see multipurpose prevention technologies, or MPTs, above).
Some of the microbicides being studied would allow a woman to get pregnant. These are called non-contraceptive microbicides. They would offer women the option of getting pregnant while still protecting themselves from infection – an option that is not available with condom use. The tenofovir one percent gel tested in the CAPRISA 004 study and mentioned above is one example of a non-contraceptive microbicide. Contraceptive microbicides would prevent pregnancy and STDs, including HIV. It is important to have both types available.
Any new product must go through strict safety testing before becoming available to the public. Health activists and researchers are closely watching over the clinical testing of microbicides to make sure that the testing is being done correctly.
It is possible that an HIV+ woman's male partner might be protected from infection if she used a vaginal or rectal microbicide. However, this would need to be tested in clinical trials. The safety and effectiveness of vaginal microbicides must be tested separately from rectal microbicides.
Microbicides could help protect HIV+ women from re-infection with other HIV strains and from other STDs.
Research on developing a vaccine to prevent HIV infection has not been successful so far. Microbicides may be available sooner than a preventive HIV vaccine. Even if a safe and effective vaccine is discovered, vaccines and microbicides will both have roles to play in the prevention of HIV.
Advocates are working with researchers and policy makers to make sure that any approved microbicide will be as affordable and accessible as possible.
N-9 products are sold over the counter as spermicides that can prevent pregnancy. They cannot prevent the transmission of HIV or other infections. In fact, when used more than once a day, N-9 contraceptive products may actually increase HIV risk by irritating the lining of the vagina. Other studies show that N-9 is even more irritating to the rectum than to the vagina.
According to the World Health Organization (WHO):
- N-9 is not effective at preventing the transmission of HIV or other STDs. It should NOT be used for disease prevention.
- Women at risk for HIV, especially those having sex more than once a day, should NOT use N-9 for birth control
- Condoms with N-9 provide no more protection against pregnancy or infection than plain lubricated condoms. Since N-9 condoms may cause irritation, they should not be used.
- Products with N-9 should NEVER be used for anal sex
Until microbicides are available, the best way to protect yourself and your partner from STDs, including HIV, is to use a male or female condom. It is also important to avoid the use of nonoxynol-9 (N-9) products if you think there is any chance you may be exposed to HIV. Getting tested for STDs regularly and getting treatment quickly if you have an STD will also help reduce your risk of HIV infection if you are exposed to HIV.